EWTX · XBRL financial data
Edgewise Therapeutics financial statements, every quarter
The same tables from 12 filings, lined up. Matched by XBRL tag: renamed lines keep their history.
How these numbers work
- Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
- Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
- * marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
- 0 means a filing states zero; a dash (—) means no filing states that number.
- “year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
- Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
- Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
- Shares outstanding come from each filing's cover page, as of the date printed there.
- Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.
Income statement
CSVFiscal quarters (EWTX's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 28* | 28 | 31 | 32 | 36* | 37 | 34 | 37 | 44* | 43 | 48 | 32 |
| General and administrative | 6* | 7 | 7 | 8 | 9* | 9 | 9 | 9 | 12* | 11 | 14 | 15 |
| Total operating expenses | 34* | 35 | 38 | 40 | 46* | 46 | 43 | 47 | 56* | 54 | 62 | 46 |
| Operating income (loss) | (34)* | (35) | (38) | (40) | (46)* | (46) | (43) | (47) | (56)* | (54) | (62) | (46) |
| Income tax expense (benefit) | year only | — | — | — | year only | — | — | — | year only | — | — | 155 |
| Net income (loss) | (30)* | (29) | (31) | (34) | (40)* | (41) | (36) | (41) | (50)* | (49) | (57) | 1,166 |
| Earnings per share, basic USD per share | (0.47)* | (0.33) | (0.34) | (0.36) | (0.42)* | (0.43) | (0.34) | (0.39) | (0.47)* | (0.46) | (0.53) | 10.71 |
| Earnings per share, diluted USD per share | (0.47)* | (0.33) | (0.34) | (0.36) | (0.42)* | (0.43) | (0.34) | (0.39) | (0.47)* | (0.46) | (0.53) | 9.65 |
| Weighted average shares, basic millions of shares | 65* | 88 | 94 | 94 | 95* | 95 | 105 | 105 | 106* | 107 | 108 | 109 |
| Weighted average shares, diluted millions of shares | 65* | 88 | 94 | 94 | 95* | 95 | 105 | 105 | 106* | 107 | 108 | 121 |
Balance sheet
CSVFiscal quarters (EWTX's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and cash equivalents | 86 | 30 | 43 | 45 | 42 | 50 | 43 | 46 | 61 | 33 | 72 | 69 |
| Prepaid and other current assets | 9 | 9 | 8 | 7 | 5 | 7 | 9 | 11 | 13 | 10 | 6 | 29 |
| Total current assets | 327 | 541 | 519 | 499 | 475 | 443 | 603 | 574 | 543 | 510 | 472 | 1,772 |
| Property and equipment, net | 10 | 10 | 10 | 10 | 10 | 9 | 9 | 8 | 8 | 7 | 7 | 6 |
| Right-of-use asset | 2 | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
| Total assets | 340 | 554 | 532 | 511 | 487 | 454 | 613 | 583 | 553 | 519 | 480 | 1,780 |
| Accounts payable | 4 | 5 | 7 | 6 | 6 | 9 | 8 | 6 | 6 | 7 | 5 | 10 |
| Accrued liabilities | 6 | 6 | 5 | 6 | 7 | 7 | 6 | 6 | 8 | 9 | 5 | 16 |
| Total current liabilities | 17 | 15 | 17 | 19 | 24 | 21 | 21 | 22 | 27 | 23 | 29 | 144 |
| Lease liability, non-current | 4 | 4 | 4 | 3 | 4 | 4 | 3 | 3 | 3 | 3 | 3 | 2 |
| Total liabilities | 21 | 19 | 21 | 22 | 28 | 25 | 24 | 25 | 30 | 25 | 32 | 147 |
| Retained earnings (accumulated deficit) | (245) | (273) | (305) | (339) | (379) | (419) | (455) | (496) | (546) | (595) | (653) | 513 |
| Total stockholders' equity | 319 | 535 | 510 | 489 | 459 | 430 | 589 | 559 | 522 | 493 | 448 | 1,633 |
| Total liabilities and equity | 340 | 554 | 532 | 511 | 487 | 454 | 613 | 583 | 553 | 519 | 480 | 1,780 |
| Common shares outstanding (cover page) millions of shares | 93 | 93 | 94 | 95 | 95 | 105 | 105 | 106 | 107 | 108 | 109 | 109 |
Cash flows
CSVFiscal quarters (EWTX's year ends in late December)
| In millions of dollars | Dec 31, 2023 | Mar 31, 2024 | Jun 30, 2024 | Sep 30, 2024 | Dec 31, 2024 | Mar 31, 2025 | Jun 30, 2025 | Sep 30, 2025 | Dec 31, 2025 | Mar 31, 2026 | Jun 30, 2026 | Sep 30, 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net income (loss) | (30)* | (29) | (31) | (34) | (40)* | (41) | (36) | (41) | (50)* | (49) | (57) | 1,166 |
| Stock-based compensation | 5* | 5 | 5* | 7* | 8* | 9 | 8* | 8* | 10* | 9 | 9* | 9* |
| Net cash from operating activities | (27)* | (29) | (26)* | (27)* | (27)* | (38) | (33)* | (35)* | (39)* | (43) | (42)* | (78)* |
| Purchases of property and equipment | 0* | 0 | 0* | 1* | 0* | 0 | 0* | 0* | 0* | 0 | 0* | 0* |
| Net cash from investing activities | 27* | (268) | 37* | 25* | 21* | 44 | (162)* | 36* | 50* | 2 | 78* | 60* |
| Proceeds from issuing common stock | year only | 239 | 0* | 0* | 0* | — | — | 0* | 0* | — | — | — |
| Net cash from financing activities | 53* | 241 | 2* | 3* | 3* | 2 | 188* | 2* | 4* | 12 | 3* | 15* |
| Net change in cash | 53* | (56) | 13* | 1* | (3)* | 8 | (7)* | 3* | 15* | (28) | 39* | (4)* |
Compare with peers
SIC 2834 and related industry codes, similar size. Each row is the latest quarter reported.
How peers are chosen
- SIC 2834 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
- Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
- Runway shows only for companies burning cash with under $10B of public float.
- * marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
- A cell reading “not reported” means the filings give no figure for that quarter alone.
| Company | Cash ($M) | Revenue, quarter ($M) | Operating cash flow, quarter ($M) | Shares outstanding | Runway | Quarter |
|---|---|---|---|---|---|---|
| Edgewise Therapeutics | 69 | not reported | (78)* | 109.5M | 1.3 quarters | 10-QSep 30, 2026 |
| Innoviva | 581 | 106 | 42* | 71.1M | — | 10-QSep 30, 2026 |
| Mannkind | 53 | 109 | (18)* | 321.5M | 6.0 quarters | 10-QJun 30, 2026 |
| Schrodinger | 247 | 64 | (48)* | not reported | 10.9 quarters | 10-QSep 30, 2026 |
| Ani Pharmaceuticals | 360 | 266 | 57* | not reported | — | 10-QJun 30, 2026 |
| Celldex Therapeutics | 47 | 0 | (57)* | 78.5M | 12.5 quarters | 10-QJun 30, 2026 |
| Spyre Therapeutics | 83 | not reported | (77)* | 95.0M | 15.7 quarters | 10-QSep 30, 2026 |
| Travere Therapeutics | 124 | 225 | 98* | 96.0M | — | 10-QSep 30, 2026 |
| Adaptive Biotechnologies | 76 | 84 | 9.6* | 161.9M | — | 10-QSep 30, 2026 |
Not investment advice. Not affiliated with the U.S. SEC.